Pharmafile Logo

antifungal

- PMLiVE

Pfizer’s flat sales focus investor attention on M&A

But CEO Ian Reed insists that there is no need for a large-scale acquisition

- PMLiVE

Pfizer takes aim at UK’s health tech industry

Offers start-ups a share of a £56k grant

- PMLiVE

Pfizer’s plans for Inlyta go awry with failed adjuvant trial

Interim data suggested there was no improvement on disease-free survival compared to placebo

- PMLiVE

AbbVie’s upadacitinib aces phase III trial

Arthritis drug outperformed both placebo and Humira in the study

- PMLiVE

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

- PMLiVE

GSK joins Reckitt in passing on Pfizer’s consumer health unit

The healthcare business doesn’t meet GSK’s criteria for returns, says Walmsley

- PMLiVE

EMA starts review of Xtandi in non-metastatic prostate cancer

The evaluation is based on positive results from the PROSPER trial

Biogen Idec building

Biogen pays $590m for Pfizer cognition drug

Early stage studies look positive for schizophrenia drug

- PMLiVE

Merck and Pfizer set to win NICE backing for Bavencio

The PD-L1 inhibitor is being assessed for the treatment of mMCC patients

- PMLiVE

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The CHMP’s positive opinion could see the drug return to market after almost eight years

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist

Hiding between the lines of any company’s ledgers is an intangible asset, invisible to most auditors, but with the potential to have a very real impact on bottom line. Pharma...

Evoke Mind+Matter

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links